46
Views
10
CrossRef citations to date
0
Altmetric
Original Article

Prognostic Significance of Serum Soluble Interleukin-2 Receptor Level in Non-Hodgkin's Lymphoma: A Single Center Study in Japan

, , , , , , , , , & show all
Pages 151-156 | Published online: 01 Jul 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Yasuhiro Oki, Harumi Kato, Keitaro Matsuo, Yachiyo Kuwatsuka, Hirofumi Taji, Kazuhito Yamamoto, Yoshitoyo Kagami & Yasuo Morishima. (2008) Prognostic value of serum soluble interleukin-2 receptor level in patients with diffuse large B cell lymphoma, treated with CHOP- or RCHOP-based therapy. Leukemia & Lymphoma 49:7, pages 1345-1351.
Read now
Elizabeth Fabre-Guillevin, Reza Tabrizi, Valérie Coulon, Alain Monnereau, Houchingue Eghbali, Isabelle Soubeyran & Pierre Soubeyran. (2006) Aggressive non-Hodgkin's lymphoma: Concomitant evaluation of interleukin-2, soluble interleukin-2 receptor, interleukin-4, interleukin-6, interleukin-10 and correlation with outcome. Leukemia & Lymphoma 47:4, pages 603-611.
Read now

Articles from other publishers (8)

Noriyuki Mizutani, Yuko Goto-Koshino, Keigo Kurata, Aki Fujiwara-Igarashi, Masahiro Sakaguchi, Minoru Asada, Koichi Ohno & Hajime Tsujimoto. (2020) Measurement of the concentration of serum soluble interleukin-2 receptor alpha chain in dogs with lymphoma. Veterinary Immunology and Immunopathology 225, pages 110054.
Crossref
Kazuhito Yoshikawa, Makiko Onodera-Kyan, Yoshimasa Kitagawa, Akira Satoh, Jun Sato, Tetsuya Kitamura, Tohru Shiga, Shiro Watanabe & Nagara Tamaki. (2018) Clinical possibility of baseline FDG-PET SUV max as a prognostic factor in patients with head and neck non-Hodgkin’s lymphoma: A preliminary study. Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology 30:4, pages 319-323.
Crossref
Y Kusano, M Yokoyama, Y Terui, N Inoue, A Takahashi, H Yamauchi, N Tsuyama, N Nishimura, Y Mishima, K Takeuchi & K Hatake. (2017) High pretreatment level of soluble interleukin-2 receptor is a robust prognostic factor in patients with follicular lymphoma treated with R-CHOP-like therapy. Blood Cancer Journal 7:9, pages e614-e614.
Crossref
Aldona Kasprzak, Rafał Spachacz, Jacek Wachowiak, Katarzyna Stefańska, Elżbieta Kaczmarek & Maciej Zabel. (2010) Tissue Expression of Interleukin 2 (IL-2) and IL-2 Receptor (IL-2Rα/CD25) in non-Hodgkin B-cell Lymphomas in Children. Journal of Pediatric Hematology/Oncology 32:6, pages 462-471.
Crossref
Tsutomu Akahane, Tominaga Shimizu, Ken’ichi Isobe, Yasuo Yoshimura & Hiroyuki Kato. (2009) Serum soluble interleukin-2 receptor levels in patients with malignant lymphoma of bone. Journal of Orthopaedic Science 14:3, pages 248-252.
Crossref
Mitsuaki Tatsumi, Hiroyuki Sugahara, Ichiro Higuchi, Hiroki Fukunaga, Hironobu Nakamura, Yuzuru Kanakura & Jun Hatazawa. (2009) Standardized uptake value on FDG-PET as a marker for disease activity in patients with non-Hodgkin’s lymphoma: comparison with serum soluble interleukin-2 receptor values. International Journal of Clinical Oncology 14:2, pages 150-158.
Crossref
Hideko Goto, Hisashi Tsurumi, Masao Takemura, Yoriko Ino-Shimomura, Senji Kasahara, Michio Sawada, Toshiki Yamada, Takeshi Hara, Kenji Fukuno, Naoe Goto, Masataka Okuno, Tsuyoshi Takami, Mitsuru Seishima & Hisataka Moriwaki. (2004) Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin?s lymphoma: in combination with the International Prognostic Index. Journal of Cancer Research and Clinical Oncology 131:2, pages 73-79.
Crossref
. (2000) Current Awareness. Hematological Oncology 18:3, pages 121-128.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.